
First-in-Class vs Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
Pharma Launch Secrets
00:00
The Challenges of Launching a New Concept
Most of my experience has been a drug that is first in its class and the class is highly differentiated. When I started at Takeda back in 1999, it was a small company. There were only really 500 of us when we first began. Creating that marketplace to be receptive to this new and novel concept is critical. And how do you have stopping power with a differentiated idea that they don't recognize?
Transcript
Play full episode